Vectura, the AIM-listed respiratory development company, confirmed that its partner Sandoz, has received Swedish marketing authorisation for AirFluSal Forspiro, a new inhaler for patients with asthma and chronic obstructive pulmonary disease.The firm, which focuses on the development of pharmaceutical therapies for the treatment of airway-related diseases, initially developed the product before licensing the asset to Sandoz in 2006.Sweden now joins the growing list of countries to approve AirFluSal, following Denmark and Germany who both authorised the product over the last two months.The receipt of the marketing authorisations in Sweden, Germany and Denmark comes after the success of completing the EU distribution procedures for the 50-500 µg (microgram) and 50-250 µg dosage forms and for the 50-500 µg dosage form Germany, Belgium, Bulgaria, Hungary, Luxembourg and Romania. Further communications will be announced after approval is received, Vectura said.In the US, the market for the single entity inhaled corticosteroids is greater than $2bn.AirFluSal will compete with current branded inhaled steroid therapies such as Pulmicort, and also with new asthma therapies and generic products.WS